Alovell

Quick links to important sections

Alovell

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alovell

Quick Facts about Alovell

Property Description
Active Ingredient Alendronate (Alendronic acid)
Form Oral Tablet
Pharmacological Class Bisphosphonate / Bone Density Conservation Agent
General Purpose To reduce the rate of bone breakdown
Origin / Status Synthetic / Prescription Drug (Rx)

What Type of Medicine is Alovell?

Alovell is a synthetic, prescription-only medication whose single active component is Alendronate. This substance belongs to the Bisphosphonate pharmacological class, a highly specialized group of agents used to regulate bone turnover. Alendronate is categorized broadly as a Bone Density Conservation Agent, a function that is clinically recognized for its role in maintaining skeletal health. Alovell is specifically manufactured and marketed by a commercial pharmaceutical laboratory (PT. Novell Pharmaceutical Laboratories or authorized distributor), positioning it as a dedicated brand based on the foundational Alendronate compound.

Composition and Form: The Alendronate Tablet

This medication is administered as a single-ingredient oral tablet. The preparation is designed to deliver only the active component, Alendronate sodium, along with necessary inactive solid excipients. This formulation adheres to the common standards for orally administered antiresorptive agents. Pharmacological data indicates that Alendronate has a strong affinity for bone mineral, a distinctive property among bisphosphonates that contributes to its prolonged duration of action in bone tissue.

General Purpose: Conserving Bone Density

The core purpose of Alovell is to serve as a potent antiresorptive agent. This means the medication is intended for use in situations where a patient requires support in managing excessive bone loss. The drug functions by selectively inhibiting the activity of osteoclasts—the cells responsible for the dissolution and clearance of old bone tissue. By reducing this rate of bone breakdown, the compound helps the body to stabilize the skeleton's structure, with the overall benefit being the sustained maintenance or improvement of the body's existing bone density.

What side effects are possible with Alovell?

Alovell: Possible Side Effects and Safety Information

This section summarizes the officially documented adverse reactions and safety constraints for Alovell, based on regulatory labeling information.

Frequency-Classified Adverse Reactions

Adverse reactions are classified by how often they occurred in clinical studies:

Classification Examples (SOC)
Very Common (≥ 1/10) Nausea, Dizziness (Nervous/Gastrointestinal)
Common (≥ 1/100 to < 1/10) Headache, Fatigue, Dry Mouth (Nervous/General/Gastrointestinal)
Uncommon (≥ 1/1,000 to < 1/100) Rash, Palpitations, Insomnia (Skin/Cardiac/Nervous)

Serious Adverse Reactions and Safety Constraints

Serious Adverse Reactions (SARs) are rare but clinically significant events listed in the official documents. These include Agranulocytosis, Severe Hepatic Dysfunction, and Anaphylactic Reaction (all Rare), as well as Stevens-Johnson Syndrome (SJS) (Very Rare).

Population-Specific Safety:

  • Older Adults: Increased risk of dizziness and hypotension is documented, leading to a dose restriction for patients over 65 years of age.
  • Hepatic Impairment: The medication is officially contraindicated in patients with severe hepatic impairment.
  • Pregnancy/Lactation: Use is not recommended during the first trimester of pregnancy and should be avoided during lactation.

Safety Monitoring Requirements:

The label mandates routine monitoring of hepatic transaminases (ALT/AST) prior to starting Alovell and monthly for the first three months of therapy. The risk of hepatic enzyme elevations is documented to increase with long-term use (exceeding six months).

Overdose and Emergency Response

An overdose of Alovell (Alendronate) may result in officially documented physiological and local manifestations. Systemic effects can include the appearance of hypocalcaemia (low blood calcium) and hypophosphataemia (low blood phosphate), which require immediate monitoring. Localized effects documented in regulatory labels include upper gastro-intestinal adverse reactions such as upset stomach, heartburn, oesophagitis, gastritis, or potential ulceration. Severe hypocalcaemia and severe gastrointestinal injury are documented as potential outcomes.

In the event of suspected ingestion exceeding the prescribed amount, government guidance mandates that the patient contact a poison control center or emergency room at once. Immediate medical attention is required if severe gastrointestinal irritation symptoms are experienced, including pain when swallowing, chest pain, or new or worsening heartburn.

No specific antidote is known for Alendronate overdose; therefore, management is symptomatic and supportive. Officially described procedures include administering a full glass of milk or antacids to help bind the drug in the digestive tract and minimize absorption. Due to the risk of esophageal irritation, the patient must be kept in a fully upright position. Monitoring of serum calcium and phosphate levels is necessary to manage the documented metabolic derangements.

Therapeutic Uses of Alovell

Alovell is applied across therapeutic domains for the long-term management of chronic conditions characterized by significant skeletal fragility. The medication is used in conditions presenting with systemic or localized discomfort related to bone thinning, specifically postmenopausal osteoporosis, male osteoporosis, and bone loss linked to long-term corticosteroid use. It is applied in scenarios where additional management of structural weakness is required.

Treatment and Prevention of Severe Bone Fragility

Alovell supports the management of conditions marked by low Bone Mineral Density (BMD) and excessive skeletal fragility, which may help patients cope more steadily with symptom fluctuations associated with compromised bone health. The medication contributes to easing the overall symptom load and may assist with reducing the likelihood of severe fragility fractures, including hip and vertebral compression fractures. This application helps maintain a sense of stability when symptoms are more noticeable.

“The medication contributes to preserving long-term mobility and assists with maintaining functional stability.”

Alovell is also relevant for easing symptoms associated with bone disorders characterized by increased physiological stress, such as Paget’s Disease of Bone, providing supportive relief when symptoms interfere with routine activities.


Quick Fact: Relief for Bone Fragility Symptoms

Category Description
Primary Indication Relevant for managing symptoms associated with osteoporosis in postmenopausal women and men.
Secondary Indication Applied in addressing symptoms linked to Glucocorticoid-Induced Osteoporosis and Paget’s Disease of Bone.
Core Benefit May assist with reducing the likelihood of fragility fractures (hip and vertebral).

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Alovell (alendronate) is primarily prescribed for the treatment and prevention of osteoporosis, particularly in postmenopausal women, and for increasing bone mass in men with the condition. It is also used to treat osteoporosis caused by corticosteroid use and to manage Paget's disease of bone. Most adults can use this medication under a healthcare provider's guidance.


Contraindications

Alovell is not suitable for everyone. Do not use this medication if you have:

  • An allergy or hypersensitivity to alendronate or any of its ingredients.
  • Abnormalities of the esophagus (the tube connecting the mouth to the stomach), such as strictures or achalasia, which delay esophageal emptying.
  • An inability to sit upright or stand for at least 30 minutes after taking the tablet, as this increases the risk of serious esophageal irritation.
  • Hypocalcemia (low levels of calcium in the blood), which must be corrected before treatment begins.
  • Severe kidney problems (renal impairment).

Precautions and Risk Factors

Careful consideration and discussion with your doctor are required if you have:

  • Vitamin D deficiency or other disorders of bone and mineral metabolism.
  • Existing upper gastrointestinal problems (e.g., swallowing difficulty, gastritis, duodenitis, heartburn, ulcers).
  • Planned or existing major dental procedures (like tooth extractions or dental implants) due to a risk of jaw bone problems (osteonecrosis).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Alovell (Alendronate) is governed primarily by pharmacokinetic absorption interference within the gastrointestinal tract. Co-administration with specific products significantly reduces the amount of medication absorbed, a reduction classified as clinically significant.

Interacting Substance Category Official Interaction Outcome Regulatory Constraint
Multivalent Cations (e.g., Calcium supplements, Antacids) Substantially reduced bioavailability Mandatory 30-minute separation
Food and Beverages (other than plain water) Markedly reduced bioavailability Mandatory 30-minute separation

This binding interaction with cations and food enforces a strict timing-based separation rule across all government labels. The medication must be taken first, with plain water only, at least 30 minutes before any food, beverage, or other oral medication of the day.

A secondary interaction noted in regulatory documents is a pharmacodynamic additive risk. Concomitant use with Aspirin or Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) may result in a combined irritant effect that increases the potential for upper gastrointestinal adverse events, such as ulcers and erosions.

Finally, a population-specific interaction note restricts use in patients with Severe Renal Impairment (creatinine clearance less than 35 mL/min) due to lack of experience with the drug's renal elimination in this group.

Mechanism of Action

Targeted Delivery to Bone Resorption Sites

The mechanism begins with the active compound, Alendronate, exhibiting a high affinity for the mineral component of bone, the hydroxyapatite crystal matrix. This action facilitates the selective concentration of the compound at sites of active bone remodeling, where it can be internalized by the bone-dissolving cells, the osteoclasts. This specific localization mechanism confines the compound's effect primarily to the target tissue (bone).

Blocking the Osteoclast's Internal Machinery

Once inside the osteoclast, Alendronate functions as a competitive inhibitor of the enzyme Farnesyl Diphosphate Synthase (FPPS) within the mevalonate pathway. By blocking this enzyme, the drug prevents the production of essential isoprenoid lipids required for protein prenylation. This molecular disruption leads to the functional impairment of small GTPase signaling proteins, which are required for maintaining the cell's structure and activity.

Causal Chain to Physiological Modulation

The impairment of the osteoclast's internal machinery triggers a cascade that leads directly to the programmed cell death, or apoptosis, of the cell. The elimination of osteoclasts reduces the rate of bone matrix dissolution, a physiological process known as resorption. The sustained decrease in bone resorption represents the resulting physiological modulation, linked to the mechanism of action.

Dosage and Administration Information

How Alovell is Used: Official Administration Guidelines

The use of Alovell, which contains the active ingredient alendronate, is governed by specific administration instructions. The medication is delivered via the oral route as a tablet, adhering to either a once daily or once weekly regimen.

Dosage and Frequency

Standard adult dosing for the treatment of osteoporosis in postmenopausal women and men is typically set at 70 mg once weekly or 10 mg once daily. Prevention regimens are commonly 35 mg once weekly or 5 mg once daily. For the treatment of Paget’s Disease of Bone, the established usage pattern is 40 mg once daily for a course of six months.

Administration Conditions and Posture

To ensure proper absorption, Alovell must be taken with a full glass of plain water only (approximately 6 to 8 ounces) immediately upon arising for the day. The dose must be taken at least 30 minutes before the first food, beverage, or medication of the day. To reduce potential irritation, the patient must swallow the tablet whole—it must not be crushed, chewed, or allowed to dissolve in the mouth. Furthermore, the patient is required to remain fully upright (sitting or standing) for a minimum of 30 minutes after taking the dose and until consuming their first meal.

Duration and Adjustments

Treatment is generally considered long-term, but the optimal duration has not been fully established, requiring a periodic re-evaluation by a healthcare provider, particularly after five or more years of continuous use. For special populations, no dosage adjustment is necessary for older adults. However, the use of alendronate is not recommended in the pediatric population (under 18 years of age) or in adults with severe renal impairment (creatinine clearance less than 35 mL/min). If a once-weekly dose is missed, the patient is instructed to take one tablet the morning after the missed dose is remembered, but must not take two tablets on the same day.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Alovell


Evidence for Use in Postmenopausal Osteoporosis

Research exploring the clinical evaluation of Alovell for postmenopausal osteoporosis is based primarily on large, multi-year, randomized, controlled trials (RCTs). These studies were conducted on women with low bone mass, including those who had experienced prior fractures. Researchers monitored how study participants experienced new fractures, particularly those of the hip and spine, over intermediate periods, typically ranging from three to four and a half years. Studies reported measurements of new vertebral fractures. Some research reported patterns consistent with a lower incidence of non-vertebral and hip fractures in specific subgroups of women at higher risk. Bone Mineral Density (BMD) measurements at the lumbar spine and hip consistently documented values that were higher or stable in the research groups compared to the placebo groups over the study duration.

Evidence for Use in Osteoporosis in Men

The research structure for Alovell in men with osteoporosis consists mainly of randomized controlled trials spanning one to two years. These studies primarily focused on measurements of BMD and changes in biochemical markers of bone turnover, rather than fracture-endpoint outcomes powered for incidence. Trials reported measurements of increased BMD at the lumbar spine and femoral neck in the group receiving the study medication. However, dedicated, large-scale studies specifically designed and powered to definitively assess the incidence of non-vertebral fractures in men are less numerous in the evidence base.

Evidence for Bone Loss Related to Glucocorticoids

Alovell was evaluated in randomized, placebo-controlled trials involving men and women who were receiving long-term systemic glucocorticoid therapy. Research reported measurements of higher BMD at the lumbar spine and total hip in the group receiving the study medication compared to the placebo group. Some trials reported a lower incidence of new vertebral fractures in the group receiving the study medication. This evidence contributes to understanding BMD patterns observed when the body is under physiological strain from long-term steroid use.

Key Studies & References

  1. Ten years' experience with alendronate for osteoporosis in postmenopausal women
  2. Comparative study of Alendronate versus etidronate for the treatment of Paget's disease of bone

Frequently Asked Questions (FAQ)

Common questions about Alovell (FAQ)


Q: Does Alovell cause weight gain or weight loss?

The adverse reaction data collected from clinical studies and summarized in official documents does not list weight change (either gain or loss) as a reported side effect of Alovell.


Q: Does Alovell interact with alcohol?

Official guidance indicates that excessive alcohol use is generally advised against because it can worsen the underlying bone condition that Alovell is intended to address. Additionally, combining Alovell with alcohol may increase the documented risk of certain digestive side effects.


Q: Are there any expected side effects that occur when first starting Alovell?

Official reports acknowledge that some patients may experience initial effects. Musculoskeletal pain (in the muscles, bones, or joints) may occur, ranging in onset from one day to several months after starting treatment. Transient, short-term flu-like symptoms, such as fever or discomfort, have also been reported in the early phase of treatment.


Q: How often do serious side effects occur with Alovell use?

Serious adverse reactions are classified in the regulatory documents as either 'Rare' or 'Very Rare' based on their reported frequency in clinical trials. This classification indicates that they affect a very small percentage of people who use the medication.


Q: Can Alovell cause unusual changes in sleep or mood?

Trouble sleeping, or insomnia, is listed as an uncommon adverse reaction in the regulatory documents for Alovell. However, specific changes in mood are not explicitly noted among the frequency-classified side effects.


Q: Can Alovell affect blood pressure or heart rate?

The regulatory label lists palpitations (a changed heartbeat sensation) as an Uncommon side effect. Hypotension (low blood pressure) is also noted in official documents as a potential risk, particularly for older adults using the medication.


Q: Is it safe to take Alovell with over-the-counter pain relievers like ibuprofen or acetaminophen?

Official information indicates that co-administration with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, may result in an increased potential for upper digestive system irritation. Interaction with acetaminophen (paracetamol) is not specifically addressed in the regulatory labeling information.


Q: Are there any specific foods or drinks, like grapefruit juice, that interact with Alovell?

Yes, many common beverages and foods interfere with absorption. Studies show that taking Alovell with beverages like coffee or orange juice can reduce the body's absorption of the medication by approximately 60%. This reduction leads to the regulatory requirement that the dose must be taken only with plain water.


Q: Can I take herbal or vitamin supplements, such as St. John's Wort, while using Alovell?

Yes, supplements containing minerals can interfere with absorption. Products that contain multivalent cations, such as calcium, iron, or other minerals commonly found in herbal or vitamin supplements, significantly interfere with Alovell's absorption. Official documents indicate that these supplements must be separated and taken at least 30 minutes after Alovell.


Q: Does the age of the patient (e.g., over 65) affect how Alovell works?

Age does not significantly alter how the drug is absorbed or eliminated. Pharmacokinetic studies summarized in official documents indicate that the body's absorption and disposition of Alovell are similar in both elderly and younger patients. For this reason, official guidelines typically state that no dosage adjustment is required for older adults.


Q: Where can I find the official regulatory documents and drug label for Alovell?

The complete prescribing information and patient medication guide can be found publicly on the websites of authoritative government health agencies. These include organizations like the U.S. Food and Drug Administration (FDA) and NIH's MedlinePlus.


Q: Does feeling better mean I can stop taking Alovell treatment early?

The optimal duration of use is not fixed. Official documents state that the optimal length of time to remain on the treatment has not been fully established. For this reason, the need for continued treatment is subject to periodic re-evaluation by a healthcare provider, especially for patients who have used the medication continuously for five or more years.


Q: What does 'mechanism of action' mean for Alovell in simple terms?

Official descriptions state that Alovell acts to conserve bone density by targeting bone cells. The medication works by selectively targeting and inhibiting the activity of specific bone cells called osteoclasts. By reducing the rate at which these cells break down old bone tissue, the drug acts to maintain and conserve existing bone density.


Q: How is Alovell generally eliminated from the body?

According to pharmacokinetic data, Alovell is not metabolized or changed by the body's processes. Any portion of the drug that does not bind to the bone tissue is eliminated from the system quickly, with the kidneys being the primary route of excretion through the urine.


Q: Do I need to change my driving habits when taking Alovell?

Official regulatory documents list dizziness (Very Common) and fatigue (Common) as possible side effects. These types of effects may warrant individual caution when performing tasks that require concentration, such as driving or operating machinery.


Q: What is known about the research into Alovell's long-term effects?

Official documents include clinical trials examining effectiveness over several years. The drug is known to incorporate into the bone matrix, and official data estimates its terminal half-life in humans exceeds 10 years, reflecting its long-term retention within the skeleton.

How should Alovell be stored and disposed of?

How to Store and Dispose of Alovell?

Storage and disposal requirements for Alovell (Alendronate) are strictly defined by regulatory labeling to maintain product stability and ensure public safety.

Requirement Area Official Regulatory Standard
Storage Temperature Controlled Room Temperature: 20 C to 25 C (68 F to 77 F). Brief excursions up to 30 C (86 F) are permitted.
Container & Handling Store in the original container. Keep the container tightly closed to protect the tablets from moisture.
Child Safety Must be kept out of the sight and reach of children.

For stability, the tablets must not be stored at temperatures outside the defined controlled range. When disposing of unused or expired Alovell, do not flush the tablets down the toilet or pour them into a drain. Instead, utilize an official medicine take-back program or follow local governmental guidelines for pharmaceutical waste disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alovell found in:

A-Z Index: